Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Mind & Matter

Mind & Matter artwork

Too Much Iron and the Aging Brain | Dr. Pamela Maher | 299

Jul 8, 20261 hr 43 minAudio

Send us Fan Mail Ferroptosis, an iron-dependent cell death pathway driven by lipid peroxidation; chronoferoptosis, in which chronic stress sensitizes neurons gradually. TOPICS DISCUSSED: Cell Death Pathways: Apoptosis proceeds through regulated steps with surface “eat me” signals that enable non-inflammatory clearance by phagocytes, whereas ferroptosis and related pathways release cellular contents that can amplify local damage and inflammation. Ferroptosis Discovery: Work on glutamate toxicity in neuronal cell lines first identified a glutathione-depletion pathway termed oxytosis; parallel studies in cancer cells renamed and generalized it as ferroptosis to highlight iron’s catalytic role. Lipid Peroxidation: Polyunsaturated fatty acids in membranes are oxidized non-enzymatically when ferrous iron reacts with hydrogen peroxide in the Fenton reaction, generating hydroxyl radicals that produce toxic lipid peroxides and reactive carbonyls that modify proteins. GPX4 & Glutathione: Glutathione peroxidase-4 is an enzyme that reduces lipid peroxides within membranes and requires glutathione as cofactor; depletion of either component removes this critical line of defense. Chronoferoptosis: Nine-day treatment of differentiated neuronal cells with chronic iron or glutathione synthesis inhibitor reduced GPX4 protein, raised basal lipid peroxidation, and increased cell death after addition of otherwise sublethal secondary stressors. Protective Compounds: Screening identified flavonoids such as fisetin and sterubin plus synthetic molecules J-147 and CMS-121 that block lipid peroxidation directly or indirectly and, in several cases, also raise glutathione levels. Human Disease Evidence: Postmortem brain tissue from Alzheimer’s and Parkinson’s patients shows elevated lipid peroxidation markers and altered iron handling in vulnerable regions; similar changes appear in animal models of multiple diseases. Dietary & NRF2 Links: Compounds that activate the NRF2 transcription factor, including sulforaphane from broccoli and certain flavonoids, upregulate antioxidant enzymes including GPX4 and may support long-term cellular resilience. ABOUT THE GUEST: Pamela Maher, PhD is a research professor at the Salk Institute for Biological Studies in La Jolla, California. Her laboratory studies ferroptosis mechanisms in neurodegenerative diseases and works to identify compounds that inhibit iron-dependent lipid peroxidation. Support the show Support my work: Good Chemistry: Personalized, science-based health consulting. Work with Dr. Nick Jikomes directly. Affiliate Partners: Visit this link to see my affiliate partners and get discounts codes for products & services to support health. For all the ways you can support my efforts.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

Nick JikomesOn the Mind & Matter podcast, we learn together from the best scientists and thinkers alive today about how your mind-body reacts to what you feed it. Before starting Mind & Matter, I spent 10 years in academia doing scientific research. I got a PhD in neuroscience where I focused on neuroendocrinology and the neurobiology of behavior. And before that, I specialized in molecular, developmental, and evolutionary genetics. I use my scientific background to help parse and translate the information that guests share on the podcast. In addition to the podcast, I write long-form, written content inspired by the show where I integrate what I've learned across episodes. I also have a free weekly newsletter where I provide you with upcoming guests, share links and provide commentary on scientific studies and research that I'm reading, and more. Visit mindandmatter.substack.com to find all of my content.

Nick JikomesHey everyone, a great way to support my efforts is to visit my support page at mindandmatter.substack.com. A link to that page is in the episode description or you can search for it on the Substack page itself. The support page has an up-to-date list of my affiliate partners. These are companies I work with and if you buy those products through those links or using the discount codes provided, those will get you a great deal on a variety of products related to optimizing physical, metabolic, or mental health and vitality. These are all products I use myself and some of them are directly related to podcast episodes or formulated by Mind and Matter guests. For example, there's a great product called Keto Citra formulated by a kidney biologist who is on episode number 186. It contains the ketone body BHB together with several minerals in a precise ratio formulated with kidney health in mind. There are also links to products like physical technology devices to track your metabolic health, digital applications to help you find and learn about food and consumer products, and more.

Nick JikomesOne product I use every day is the AquaTrue water filter. I recommend this to everyone because it gets everything out of your drinking water, heavy metals, microbes, endocrine disruptors, microplastics, you name it. Other charcoal or gravity-based filters that a lot of people use don't get everything out. They just get some of the stuff out. So I really like the AquaTrue product. You can look for a link to my affiliate partners on my support page or directly in the episode description to this episode, or you can go to mindandmatter.substack.com to find it there. Dr. Pam Lamar, thank you for joining me for a second time on the podcast.

Pamela MaherOh, yeah, I'm happy to be here.

Nick JikomesDo you want to just remind everyone a little bit about who you are and what your lab studies?

Pamela MaherYeah. So I'm a research professor at the Salk Institute for Biological Studies in La Jolla, California. And my laboratory has been interested for a number of years in what was but originally described as a cell death pathway called, that's now named ferraptosis and its potential role in neurodegenerative diseases. And we've both explored this at a basic research level, but also use this pathway as the basis for drug development or potential therapeutics for neurodegenerative diseases.

Nick JikomesSo basically you study cell death, and in particular, this specific form of cell death called aferoptosis, which turns out to be relevant in the context of neurodegenerative disease. And if we think about it in very basic terms, neurodegeneration, when our neurons are born and they're done maturing, those are the neurons we're left with. With few exceptions, those neurons can't be replaced. And so if they die, we have a problem because they can't grow back and we get neurodegeneration, Alzheimer's disease, and other things that people are familiar with.

Nick JikomesBut if we kind of think about this at a high level and get people thinking about some of the basic biology here, Can you talk a little bit about the basic forms of cell death that are out there that we might read about in textbooks? What are the different ways that cells can die, both in the sense of when they're supposed to die or healthy versions of cell death, and then versions where it's not supposed to happen and it results in damage that can't be undone?

Pamela MaherYeah, there's a number of different kinds of cell death. The first one that was described is a process called apoptosis, which was originally described in the, I believe, in the early 1990s, and is a called a, it's a regulated cell death pathway. It goes through specific steps and there are the specific markers for that pathway. The most commonly used is cleavage of an enzyme called caspase-3.

Pamela MaherApoptosis can be activated by several different inducers and it eventually, involves loss of proteins from the mitochondria and activation of this enzyme, Caspase-3. It plays a role in brain function. in development. So it's been implicated, particularly since it was sort of the first cell death pathway described.

Pamela MaherIt was initially implicated in a variety of diseases. But as I said, it also plays an important role in development, particularly in tissues where you have excess cells and you that are produced during development and they need to be removed. The other thing that distinguishes apoptosis from most other cell death pathways is that when cells start to undergo this process, they put a signal on their surface of phosphatidylethanolamine that says essentially, eat me. And so they are cells that are undergoing apoptosis tend to be taken up by cells of the immune system, like like phagocytic cells, like macrophages.

Pamela MaherAnd so they don't release their contents into the extracellular environment. So unlike other cell death pathways, apoptosis is tends not to induce a major inflammatory response. I mean, because these cells eat them and they don't, the cells, the phagocytic cells eat them and digest them rather than having the cells burst open and release their contents into the surrounding tissue or blood or whatever. And that can, it stimulate a major inflammatory response, which can be as detrimental as the loss of the initial cell.

Pamela MaherThere are other types of cell death, a number of necroptosis, which is a distinct pathway. that involves a set of enzymes that are activated when this pathway is turned on. Parthenotosis, which is yet another pathway that involves overactivation of an enzyme called PARP. And then there are several other cell death pathways that have been described that are activated under distinct situations.

Pamela MaherThere's a recent one that's received some attention that seems to be more related to cancer, or cancer-related diseases. consequences of chemotherapeutic drugs called cuproptosis that involves copper. But there's a number of different pathways out there and they all are distinct in terms of the different steps that are involved. And they also, a number of them have clear markers that you can use to identify distinguish them, their activation in either cell culture models or even for pathways such as apoptosis and necroptosis and parthenotosis, I'm not sure I'm saying it right, the markers that you can also can be used in tissue, in vivo, in like tissue sections.

Nick JikomesSo there are multiple ways that cells can die. There's apoptosis, there's a number of other cell deaths that can happen. The end result of all of these is that the cell goes away, it gets cleared out, it dies. It's not there anymore. But the specific steps, the causes or the inducers of all of these different forms of cell death can be different. And the steps and the level of regulation can differ between these forms of cell death in terms of what's causing them and how they play out and how the cell might be, say, communicating with the immune system in order to be cleared out in the end. One of the things that you said that I think is important is in apoptosis, for example, programmed cell death, the cell is basically sending out a signal or putting a signal on its surface to tell the immune system to clear it out so that the cell can be removed safely, let's say, without the cell leaking or bursting open and causing more problems.

Nick JikomesHow important is it when a cell dies that it sends out a signal on its surface to be engulfed by a macrophage or something like that versus gets physically torn open and releases its insides to the external environment?

Pamela MaherI think it depends on the situation where the cell is damaged or dying. I think in terms of certain types of injury, particularly in peripheral injuries, probably releasing some of those molecules can be important in terms of the actual healing process. So bringing in various cells that can in the long-term contribute to the resolution of the injury. In the brain, I think, particularly in the context of aging and neurodegeneration, then that's probably makes things worse.

Pamela MaherSo I think this release can be, have been, in certain circumstances, beneficial. And as I said, in certain types of acute injuries, I think there's growing evidence that actually allowing some of this inflammatory process to proceed is actually helpful. But in other contexts, particularly where the system is maybe not as healthy, then so in these injury conditions, you get a the inflammation and you get a process of resolution, but perhaps particularly in the brain, particularly in the context of aging and neurodegenerative disease, that resolution process doesn't occur.

Pamela MaherSo if cells start releasing their contents, this leads to sort of a feed forward mechanism where you're getting more and more release of various components of the cells that can both aggravate the inflammatory process, but also directly, potentially directly damage surrounding cells. So it's, I think context is important.

Nick JikomesYeah, yeah. So, in the abstract, what are the major ways, what are the major things or reasons why cells need to die? Obviously, one of them is just physical damage. If I bump my knee or get a cut or I'm burned, there's a bunch of cells in some patch of tissue that get physically broken. They're split open, there's holes poked in them, all of their insides are spilling out. And all of that stuff needs to be vacuumed up basically by the immune system so that things can be rejuvenated, new cells can grow there and be put in place and that type of thing. What about cells that aren't physically like opened up through physical injury. What are some of the major inducers of a cell that will cause it to undergo apoptosis, say, to actually decide to send a signal that says, come eat me immune system?

Nick JikomesAre we talking about infection here, or are we also just talking about something inside of the cell not functioning properly?

Pamela MaherThis isn't really my area of expertise, but infections can cause that. they can lead to, so the release of DNA into the cytoplasm in cells, either from mitochondria or potentially from a DNA viral infection or something, or I suppose bacterial infection, potentially can activate, pathways that I believe can lead to cell death. The other, and RNAs as well, viral, different RNAs can induce those. in cells that can eventually lead to death.

Pamela MaherAs I said, this isn't really my area of expertise.

Nick JikomesSo there's a bunch of ways that cells can die. There's different pathways, different mechanisms. But ultimately, well, let's just think about this next. a lot of cells can be replaced. So it's sort of okay in a sense that they die in certain contexts, at least because you could build a new one, you can build a new skin cell, you can build a new whatever cell. But of course, there's some cells that can't be replaced. One of those is the neuron, most mature neurons can't be replaced. And we'll probably get into that in the context of neurodegeneration.

Nick JikomesBut is there anything that we should talk about upfront about I don't know, protective mechanisms that maybe are special to post-mitotic non-dividing cells like neurons. Do they have any special systems in place to try and prevent things from going wrong and trying to prevent cell death from happening because they can't be replaced?

Pamela MaherYou know, that's an area, that's an interesting question, but it's an area that really hasn't received all that much attention. I think people are starting to think about that more, this concept of resilience. And so I was just reading an article a summary of some work that had been done recently where they're trying to actually, in the context of a variety of particularly of genetic diseases, particularly those that seem to manifest very differently, even within a family say that people, multiple people carry the gene for this disease, but when they get it and how severe the symptoms are in certain diseases can vary quite a lot.

Pamela MaherAnd I until people haven't really understood why. And now they're starting, because of all these big databases that are available, and how cheap DNA sequencing has, and readily available, has become, different groups have started to explore this to see if in the people who have this specific genetic mutation, but seem to manifest it either not at all, or the symptoms are very mild or occur only much, much later than say the kind of traditional picture of the disease. Trying to identify genes that might be protective in the context of the disease.

Pamela MaherIn this paper I was reading, there was an example with sickle cell anemia. And some people with it have, they recognized a number of years ago, have much milder symptoms. And it turns out that they are able, they don't shut down the synthesis of a kind of an embryonic form of hemoglobin that is not susceptible to the same mutation that gives rise to the, the form of hemoglobin that leads to the damage in sickle cell disease. And that's actually how the gene modification approach that they're using to treat sickle cell disease relied on discovering this, this...

Pamela Maherknocking down this protein that's normally involved in turning off the sort of embryonic form of hemoglobin. So they're taking this, trying to identify these genes for a number of of genetic diseases that might provide resilience. So yeah, there seem to be, at least in certain individuals, the ability to modulate the consequences in this context of genetic disease, but you could probably extend this to aging or exposure to various toxins or other things like that. that people, and it's, some people are going to be much more resilient.

Pamela MaherAnd so, but there hasn't been until more recently much exploration of that concept.

Nick JikomesAnd so can you give us, so we're going to talk about Feroptosis and some of the biology related to acute versus chronic stress. iron biology, polyunsaturated fats and oxidative stress and sort of tie all these things together for people so they can understand how this process unfolds. I want to ask you a little bit about some basic iron biology to give people a little bit of a background here. Probably the most famous role, I think, for iron in the body is its role in hemoglobin to help carry around oxygen in the blood.

Nick JikomesBut when we're thinking about individual cells and what's going on inside of them, Can you give us a basic picture of what are some of the key things that iron is doing inside of our cells that makes it just so important?

Pamela MaherWell, iron plays a key role in the function of a number of different proteins in the cell. Some of the most important of those proteins are in the mitochondria and they are involved in energy production as well as other functions of the mitochondria. And there's a whole family of proteins called iron sulfur cluster proteins. So they have iron as part of their key catalytic activity.

Pamela MaherAnd these are found both in mitochondria, but also in the cytoplasm. And when those, in the, when there isn't enough iron, those proteins don't function properly. And there's quite a large number of proteins that involve iron enzymes that are lipoxygenases, which can produce, lipid peroxides, but also have important roles in immune response and other processes. Those are iron-containing proteins.

Pamela MaherSo there's a number of different proteins that are important for cellular function that require iron for their activity. And... Yeah, so when there's not enough iron or either there's not enough iron or the iron handling is somehow messed up or actually the ability of these proteins to incorporate The formation of these iron-sulfur clusters is actually fairly complex, involves several enzymatic steps. And so when that is somehow altered detrimentally, that can also, the cell thinks it, I think, thinks it doesn't have enough iron even when it does.

Pamela MaherBecause it can't make, I think the cell is telling itself, I need these proteins, I need these. But because the process of making them is somehow disrupted, there becomes a problem. So the cell keeps bringing in iron to make them, but then it can't do it.

Nick JikomesSo in addition to helping us transport oxygen through our bloodstream, iron is important for mitochondria. And basically almost all of our cells have mitochondria. Most of our cells have a lot of mitochondria. And as people probably know, mitochondria are the epicenter of oxidative metabolism. This is where most of our ATP comes from. And iron ions have multiple states they can exist in. They can have a plus two or plus three charge. So basically they can lose or gain an electron. And so when we think about mitochondrial biology, there's the electron transport chain. Mitochondria basically are moving electrons as part of the elaborate mechanism they have to make all of this ATP. And iron is involved in basically some of the mechanisms, some of the steps in that chain that are moving electrons around in order to generate ATP.

Pamela MaherYeah, yeah, at least in the function of the proteins that are involved in the different steps of the electron transport chain, yeah. It doesn't... Yeah, I'm not totally sure that iron is... Changes in the redox of iron from iron two to iron three or back are directly involved in the electron transport chain, but it is involved in the function of proteins that form the different complexes of the electron transport chain.

Nick JikomesSo yeah, iron's important for mitochondrial function. And if we ignore the details, if the mitochondria break down in some way, then the cell's got a real big problem. So this maybe starts to hint at how iron could potentially be a good signal to tell a cell whether or not its mitochondria are functioning properly.

Pamela MaherYeah, potentially.

Nick JikomesAnd so, how did you come to the discovery of feroptosis? Can you give us just a very basic summary of how that unfolded?

Pamela MaherWell, this goes back quite a number of years. So, a long time ago, we were actually interested in the discovery of feroptosis So in nerve cells, there've been known for, there was a number of years that the activation of what are called excitotoxic glutamate receptors can be harmful to nerve cells and cause their death. But these receptors are also involved in synaptic transmission, so sending signals between neurons. But over, activation of these receptors, as I said, could result in nerve cell damage and death.

Pamela MaherAnd people had been searching for ways to study this in cell culture outside the animal to be able to do more mechanistic type studies. And so there'd been a real search for particularly or potentially nerve cell lines that could be cultured indefinitely. Because all of the studies that were done, and actually still are done, are on primary neurons that have to be isolated frequently from rodent embryos. And so a long time ago now, Dave Schubert, my late collaborator, and I were interested in, he was particularly interested in trying to identify a nerve cell line that had, was responding, that displayed this excitotoxicity in cell culture.

Pamela MaherAnd there was a publication he read that described a line. And so he got this line, and it turned out that they did not have excitotoxic receptors, but they were still quite sensitive to glutamate in that it was still able to kill them, but not at a high level. at a higher concentration that normally induced excitotoxicity. And also we, through PCR, showed the cells didn't express excitotoxic receptors. And about the same time, a group at the Johns Hopkins University described a high concentration also described glutamate as killing nerve cells through a process that didn't seem to involve excitotoxic receptors. And so we were, became intrigued by this pathway because, you know, the cells, as I said, it was a higher concentration of glutamate that's usually involved in excitotoxicity, but still at a levels that could be achieved in vivo under certain circumstances of glutamate. So we started exploring it a lot further. And based on this previous work from the group at Johns Hopkins, we confirmed that it involved loss of glutathione seem to involve the inhibition of a transporter which exchanges cysteine, the oxidized form of the amino acid cysteine, which is rate limiting for the synthesis of glutathione, which is the major intracellular antioxidant. that set up a cascade of changes in the cells that eventually led to death. And so we decided to pursue the different steps in that process, and found that it involved the, you know, Following glutathione loss, you've got a major increase in reactive oxygen species production, particularly out of the mitochondria, and activation of lipoxygenases, which are these enzymes that can generate lipid peroxides.

Pamela Maherand then influx of calcium and cell death. And we described this pathway as oxytocin. But it remained sort of a niche pathway because we described it specifically in nerve cells and it was associated with glutamate, which is an enzyme is more associated with nerve cells than other types of cells.

Nick JikomesYou didn't know at that point how general this form of death was?

Pamela MaherWell, we did do some studies even before that. We showed that we could kill other types of cells, except it took quite a lot of higher levels of glutamate. the relevance to these other types of cells, at least in the physiological context, wasn't entirely clear. But we did show in a number of studies, like with different types of fibroblasts, that we could induce this pathway.

Pamela MaherAnd also, we did this with, I have a collaborator, Anne Hanekin, that works on the eye, is a retinal surgeon. And we had a number of papers showing that different types of cells in the eye that are impacted in macular degeneration, so retinal pigmented epithelial cells, and also the cells in glaucoma, retinal ganglion cells that also seem to be quite sensitive to this pathway. So we knew it was more general than just nerve cells, but we didn't realize how general. And others, just to step out, others had also shown that other types of cells in the brain, such as oligodendrocytes, are very sensitive to this pathway.

Pamela MaherBut then in 2012, Brent Stockwell's lab published a paper where they read They described this same pathway, but in the context initially of cancer cells, and they called it varroptosis because they highlighted the role of iron in the pathway. We knew that iron was involved, but because we had shown that iron chelators could protect from the activation of the pathway, but that hadn't been a big focus of our work probably. mistakenly. But so the Stockwell lab showed, they used, and they did this through a synthetic molecule called arastin, which it turned out inhibits the same transporter that exchanges cysteine for glutamate, only the way glutamate blocks it is by directly, it's a anti-porter, so it exchanges cysteine for glutamate, so it's just excess extracellular glutamate blocks the cysteine uptake, whereas this small molecule called arastin, irreversibly inhibits this exchanger, but it's the same protein. And the consequences are the same in that you get a depletion of glutathione in the cells, which sets off this whole pathway.

Nick JikomesSo glutathione is a major antioxidant. Antioxidants help protect our cells against oxidative stress, which comes from the use of oxygen in our cells. Obviously, a major site at which oxidative metabolism is happening and oxidative stress and reactive oxygen species are generated are the mitochondria, right? Because that's where the electron transport chain is. That's basically why we breathe oxygen. It's got to go there. That's a site of oxidative stress, but also that's a lot of where the action is in terms of antioxidants, because the whole point of an antioxidant is to help protect the cell from oxidative stress. Before we dig into that a little bit more, I want to ask you a little bit more about iron.

Nick JikomesSo we said it's important for certain aspects of mitochondrial function. You often hear a lot about the concept of iron storage. Our bodies store iron in some organs. We store a lot of iron. At the level of organs and at the level of cells, how and why is actually iron stored? Can you give us just a basic sort of picture of that?

Pamela MaherYeah. So the major storage molecule for iron is a a complex called ferritin that's made up of both two proteins, both ferritin heavy chain and ferritin light chain. And these come together in complexes of large numbers of these proteins, like up to 24 or more. And they, can store hundreds, if not more, or thousands of iron molecules in this complex, and then release it when it is set.

Pamela Maherit's it's needed for say the synthesis of this um iron iron cluster proteins or or this active synthesis of other types of proteins that that require iron correct got it so basically ferritin there's a protein complex that can stick to a bunch of iron atoms and hold on to them store them

Nick Jikomesto use them if and when they're needed. So there must be a lot of need inside of cells to have iron stored up and ready to go just in case.

Pamela MaherYeah, there seems to be. Well, ferritin can be very quickly induced by excess iron. So ferritin levels go up. in cells and at least in cell culture models within a few hours. Yeah.

Nick JikomesSo basically the cell can pretty quickly change its capacity to store iron.

Pamela MaherYes. Yeah.

Nick JikomesAnd is that related to problems that can come from too much iron being around?

Pamela MaherIt can be a marker of too much iron being around, but it can also be a marker, I mean, it can be good and bad. I mean, it can be good of, I mean, a marker of too much persistent, like too much iron persisting for an extended period of time, but it's also an indicator that the cell or the tissue is responding. It can be, as I said, it can come up and it can go down as well. So it may be, changing just with various in peripheral organs such as the liver or something it I'm not actually don't know this for sure but it could vary with your diet or or other environmental exposures such as that.

Nick JikomesSo iron is important for mitochondrial function. The cell's got ways to store it and change how much can be stored. Mitochondria are the site of oxidative metabolism in our cells. They're also the site of a lot of the reactive oxygen species production. So the sparks flying off the engine that can potentially damage components of the mitochondria or the cell But we've got glutathione and antioxidants that can help contain those reactive oxygen species. And then obviously, it should be pretty intuitive that these things should be in good balance, right? You can handle a certain amount of oxidative stress because you've got antioxidant systems like glutathione, but obviously if those antioxidant systems for some reason get depleted or there's just too much reactive oxygen species production, it overwhelms the antioxidant systems and then the mitochondria or other parts of the cell can take on damage and experience oxidative stress more.

Nick JikomesYou've also said something once or twice about lipid peroxides. How do lipids and lipid peroxides come into the picture when we think about oxidative stress and cell function?

Pamela MaherSo lipid peroxides are generated from what are called polyunsaturated fatty acids, which are one of the major constituents of cell membranes, and they help to make them flexible. So because they have a double bonds, they are these lipids, these, fatty acids in the membrane go into the, yeah, the outside, what faces the outside of the cell or the cytoplasm are the head groups, which are called phosphatases. And then the lipid molecules themselves go into the membranes. And you want a membrane that is not entirely stiff, but has some flexibility for cells to move around and move around.

Pamela Maherand if they're a cell in the bloodstream, then to be able to squeeze through capillaries and blood.

Nick JikomesSo you want your membrane to be fluid enough to be a little pliable and bendable so that it's not so rigid. Basically what you're saying here is there's a trade-off. The more polyunsaturated fats in the membrane, the more fluid and elastic the membrane is, those red blood cells can squeeze through tight spaces and so on and so forth. But there's a downside to having a lot of those polyunsaturated fats, right?

Pamela MaherYes. So they can be what are called oxidized. So oxygen molecules can bind to them. And that can happen two ways. It can happen enzymatically through the activity of those enzymes I mentioned previously, like poxygenases. And probably more as importantly, it can happen non-enzymatically through a process called the Fenton reaction. And this involves, is the interaction of ferrous iron, which is Fe2, F plus two, with hydrogen peroxide. And hydrogen peroxide is produced by the mitochondria and sort of a, byproduct.

Pamela MaherAnd it's also produced by a couple of other enzymes within the cells, like NADP oxidases. So the hydrogen peroxide interacts with ferrous iron to generate what's called a hydroxyl radical, which doesn't move very far, but is extremely reactive, and particularly can react with these double bonds in unsaturated fatty acids. generate, oxidize them. So iron, excess iron, free iron, what are called labile iron, plays a key role in generating these lipid peroxides.

Pamela MaherAnd the lipid peroxides themselves, not only does it alter the fatty acid chain of the the phospholipids in the membranes, but it also can lead to the production of what are called reactive carbonyl species, that these can break down and form a small molecule that, based on the lipid fatty acid chain, that can then interact with phospholipids. particularly with proteins, and when it does so, it can alter their function and it can also promote, in some cases, aggregation. the consequences of lipid peroxidation are not just alterations in the membranes themselves, but also potentially these modifications to various proteins, which can have additional consequences on top of affecting potentially membrane function.

Nick JikomesSo reactive oxygen species and oxidative stress can cause unregulated oxidation of these polyunsaturated fats. And when this lipid peroxidation happens, it can generate highly reactive lipid peroxides. These are basically just molecules that come from the oxidation, the non enzymatic unregulated oxidation of these polyunsaturated fats. And these things will then just go on and react with something like a protein or some other cell component and break its function.

Nick JikomesSo when we think about cell damage or cell dysfunction, this is sort of like where the rubber meets the road. We're generating reactive molecules from oxidation of lipids that then go touch a protein or something else and break or hamper its ability to do its normal intended function.

Pamela MaherYes. Yeah.

Nick JikomesOkay, okay. And so reactive oxygen species can oxidize polyunsaturated fatty acids, and there's a lot of them in the double membrane of mitochondria. And of course, that's where a lot of the oxygen and oxidative metabolism is happening. Where exactly does iron come into the picture here?

Pamela MaherYou mentioned ferrous iron, but how is this sort of facilitating the- Well, because it interacts with the hydrogen peroxide that's produced sort of by both comes from mitochondria, but also comes from several other enzymatic sources. And that through this chemical reaction called the Fenton reaction generates these hydroxyl radicals that directly react with the unsaturated bonds in phospholipids to oxidize them.

Nick JikomesI see. So basically this Fenton reaction generates some of these cell toxins by oxidizing lipids. And if there is too much of iron basically floating around, if you've got an overabundance of iron, you're going to tend to get more of these toxins produced?

Pamela MaherYes.

Nick JikomesYeah. Got it. And so when we think about the full set of steps to go from healthy cell to ferroptotic cell death. What is actually triggering the final phase of this when the cell actually dies? I would imagine there's just an increased oxidative stress burden, you're getting more of these lipid peroxides forming, they're damaging proteins and stuff. At sort of the end of this causal chain, what is causing the ferroptosis and the actual cell death to happen?

Pamela MaherThat is actually still being debated. We showed a number of years ago and in other studies more recently, that there is an influx of calcium into cells that seems to be very shortly before the actual death. Not everybody agrees with us, but I still think that that plays an important role. Exactly what mediates that transport, There's been a couple of, it's not fully clear.

Pamela MaherSo that comes as a result of these changes in both the the cell membrane and also the mitochondrial function.

Nick JikomesBut, you know, ignoring some of the gory details here, essentially what we're talking about, if I'm hearing you correctly, is for some reason, there's an increase in oxidative stress in the cell. Maybe antioxidant systems are depleted. Maybe you're producing more ROS, maybe both. Iron is part of the picture here, you get more lipid peroxidation, you get more of these highly reactive toxins produced, they start breaking proteins and other things in the cell, and at some point the cell is basically just so broken and dysfunctional that it's going to be killed.

Pamela MaherWell, it's going to die. Yeah.

Nick JikomesYeah. It's going to die. And when it dies this way, through ferraptosis, is it just that one cell is going to die and go away? Or can dying this way actually cause nearby cells to also have problems?

Pamela MaherIt can also cause nearby cells to have problems. I think there's one group, at least, that showed that there, at least in some models, they've seen sort of waves of theroptosis. in tissues where all the cells are connected. So that, yes, I think there's some idea that because the cells, unlike the apoptosis that I mentioned earlier, the cells release their contents and some of those contents can be damaging or activate various processes in other cells.

Nick JikomesWhen we think about this happening, ferraptosis, is this the type of thing that happens relatively quickly or does it play out over an extended period of time? Are you going to have some stressor that induces a bunch of oxidative stress and the cell dies pretty quickly or can this play out over much longer periods of time?

Pamela MaherWell, this has been sort of a big question in the field, because it can happen very quickly, particularly in culture, which is where many people study it. But when you're talking about it in the context of, neurodegenerative, age-related neurodegenerative diseases or other diseases that occur over even peripheral diseases that occur over a lengthy period of time, then that that's sort of a an oxymoron. I mean it's it's hard to apparent contradiction because if it happens really quickly but that always happens really quickly, then how do you say, well, it's involved in something that some disease or that happens over an extended period of time? And this is where we came up with this idea of therapeutic stress or chronotherapeutosis that we're calling it, where some of these changes such as decreases in glutathione, increases in iron, increases in lipid peroxidation, accumulate slowly over time, leading to changes in cellular function and perhaps loss of some level of resilience to various insults. But the cells can stay in this state. They're viable and I mean, I guess would depend on the degree of changes functional, but they are not fully healthy. And so based on a lot of the studies I've read on on Feroptosis, often people, particularly that involve studies in animals, they see these changes like loss of, decreases in glutathione, increases in lipid peroxidation, changes in some enzymes involved in the, levels of enzymes involved in the therapeutosis pathway, but they often don't really see much cell death. And so I think that this, therapeutic stress or chronophereptosis actually may be as important or more important than the actual death because I think it sets the cells up for not functioning fully and also sets them up to be more sensitive to other types of insults, either directly related to therapeutosis or related to other types of stress that then make them more likely to die when exposed to those other stresses.

Nick JikomesSo basically under different conditions, a cell's sensitivity or propensity to be killed off like this can change. And I can imagine at least a couple of different ways that a cell's sensitivity to these types of stressors could change. One of them would be antioxidant depletion. If for some reason your glutathione antioxidant system is going down, then you're less able to cope with the normal levels of oxidative stress that a cell is going to have to deal with. Perhaps another one would be the amount of lipid peroxidation that can happen, which I imagine is going to be a function of how many of these polyunsaturated fats are actually in the membrane. Can you talk about what some of these levers are that actually make a cell more sensitive to oxidative stress and ultimately ferropetosis?

Pamela MaherWell, one of the key enzymes that I haven't brought up yet that sort of ties glutathione to lipid peroxidation is an enzyme called glutathione peroxidase-4. And there's a family of glutathione peroxidases. I think there are seven or eight of these enzymes. and as the name suggests they use glutathione and they require glutathione for their activity and they remove various forms, various oxidants from cells.

Pamela MaherGlutathione peroxidase-4 is the only one of this family that can remove lipid peroxides from lipids in membranes. So it converts them to lipid alcohols, which are non-toxic as opposed to the oxidized form. And The glutathione peroxidase-4 is absolutely dependent, as I mentioned, on glutathione for activity. So if glutathione levels, even if there's plenty of glutathione peroxidase-4 around, if there's a real shortage of glutathione, then this enzyme can't perform its function.

Nick JikomesSo there are antioxidant enzymes, like the ones you're talking about, and they are proteins, they're enzymes that can basically neutralize these toxins, these lipid peroxides that we've mentioned, but they need glutathione to be present. So you've got glutathione, you've got these peroxidases, they both need to work together. And even if you get some lipid peroxides formed from these polyunsaturated fats getting oxidized in the mitochondrial membrane, say, they can basically be handled and neutralized and taken care of by this antioxidant system, the peroxidases working together with glutathione. But if for some reason the peroxidase isn't there or your glutathione's been depleted, now there's lower capacity to actually handle these highly reactive toxic lipid peroxides.

Nick JikomesAnd instead of removing them from the membrane and neutralizing them, they can cause damage and cause damage to spread.

Pamela MaherYes. Yeah. Yeah. And so the glutathione peroxidase is critical in the context of the asperoptosis pathway, because as I said, it's the only enzyme that can remove lipid peroxides from lipids in membranes. Some of the other glutathione peroxidases play important roles in removing other types of reactive oxygen species, and again, they are also impacted if glutathione levels go down. And there's actually a form of glutathione peroxidase that seems to be specific for mitochondria. So that does highlight the need to protect mitochondrial membranes as well as the plasma membrane.

Nick JikomesAnd, you know, thinking about the causal chain here, can you have cells where say they're experiencing an increase in oxidative stress, there's more ferrous iron around and or there's more reactive oxygen species being produced, They've got these peroxidase enzymes and this glutathione antioxidant system to handle that for some reason. Can you induce increased oxidative stress, increased iron overload, but then prevent the lipid peroxidation and prevent the cell from dying?

Pamela MaherSo the people, a number of labs have developed compounds that inhibit, that either directly inhibit lipid peroxidation, or can also, from through various processes that inhibit lipid peroxidation, indirectly inhibited. So there are some of the first paraptosis inhibitors that were described are direct inhibitors of lipid peroxidation. And we, several years ago now, we did a screen of a variety of natural products and found, interestingly, that many of them had no effect on actual just reactive oxygen species production, but they could block lipid peroxidation. And most of them did it directly.

Pamela MaherSo we could generate, test this in a synthetic, what are called liposomes, where we incorporated a dye that we can use to monitor the oxidation. And we could show that liposomes a variety of compounds that we identified that were protective against ferruptosis, were direct inhibitors of lipid peroxidation. And this has become a bit, can be a bit of a problem if you're looking at pathways involved in ferruptosis, because, you know, some there have been molecules that suggested some signaling pathway was involved, but it actually turned out that the classical or standard inhibitor of that pathway was a direct inhibitor of lipid peroxidation.

Pamela MaherSo even though using this inhibitor blocked the baroptosis, it wasn't because necessarily it was inhibiting this pathway, but it had, because of the nature of its structure, it could act as a direct inhibitor of lipid peroxidation. So that's something that, yeah, if you're proposing a novel pathway sometimes and you're using only like a single inhibitor of that pathway, you gotta be a little careful.

Nick JikomesYeah. So there are compounds out there that can prevent lipid peroxidation and help prevent cell death, ferrooptotic cell death, even if the cell is experiencing an increase in oxidative stress, it's producing more reactive oxygen species. You're just, this compound is just getting away in the way of the downstream step that would initiate lipid peroxidation that would then trigger the cell death.

Pamela MaherYeah, there's also compounds that can reduce fatty acid synthesis. Fatty acids, for reasons that aren't totally clear, because the production of unsaturated fatty acids is quite complicated, but it seems that compounds, some compounds that reduce fatty acid synthesis either directly or indirectly or promote lipid oxidation can also be protective. not acting as direct inhibitors of lipid peroxidation, but somehow it's not fully clear, reducing the substrate load, I guess.

Nick JikomesSo a couple of different ways to help prevent lipid peroxidation induced cell death. One would be to neutralize or take care of the lipid peroxides, the toxins that are formed as they're being formed. Another way would be to decrease their production or the rate of production by, say, lowering polyunsaturated fatty acid production.

Pamela MaherYeah. And then there's also reducing upstream reactive oxygen species production, like hydrogen peroxide production, that could lead to the generation of the hydrosyl radicals that induce the lipid peroxidation. And also it's been shown, so as I said, lipid peroxides can also be generated enzymatically. And there are a number of inhibitors of the lipoxygenase enzymes that do this.

Pamela MaherAnd so those inhibitors have also been shown to be fairly effective, at least in models of feral ptosis.

Nick JikomesIn essence, what we're talking about here is there are components of membranes like mitochondrial membranes, like polyunsaturated fats. And if you burn them, if you take an oxygen and do oxidation, they're basically going to release toxic fumes. And there's multiple ways that a cell might handle or regulate this problem. You can sort of quench or neutralize the fumes as they're being formed. you could put less dry kindling in the membrane so that there's less of it being lit on fire, or you can decrease the amount of sparks that are flying off your machines in the form of reactive oxygen species to light that on fire to begin with. Is that roughly like an idea how people can start to conduct it?

Pamela MaherYeah. Yeah, I think that's fairly accurate, yeah.

Nick JikomesSo what are some of the compounds that you guys have seen? What are some of the specific compounds that help prevent lipid peroxidation from happening?

Pamela MaherWell, yeah, the original compounds, ones people use in a lot of research studies are two compounds called ferrostatin, which was developed by Brent Stockwell's lab and leproxtatin, which was developed by Marcus Conrad's lab. But in terms of therapeutics, those have not, they don't, they have poor pharmacokinetics and they haven't, they've kind of worked in animal models, in terms of actual drugs for humans, I don't think they're, I mean, they haven't been pursued, I think, because of the poor pharmacokinetics. But we've, so we've identified a number of compounds and other, well, yeah, we've identified a number of compounds that, you know, are very effective against this pathway, mainly more by probably indirectly inhibiting lipid peroxidation. There's several natural products that we've been working on.

Pamela Maherfor a number of years, a couple of flavonoids, one called Vicetin, another called Sterubin. And then we also have some synthetic molecules, one based on the polyphenol curcumin, that's called J-147, and another one based on the flavonoid Vicetin called CMS-121. And both of those, so the flavonoids themselves work at like low micromolar concentrations, but the synthetic compounds work at nanomolar concentrations to block this pathway. And they seem to act at, I think the most effective compounds actually seem to act at multiple steps.

Pamela MaherSo both Fisetin and CMS-121 as well as Darubin are not only able to They are able to increase glutathione levels significantly, and they also can reduce lipid peroxidation, but in some cases indirectly. J147 doesn't affect glutathione levels, but it very much indirectly reduces lipid peroxidation.

Nick JikomesAnd so set us up for understanding your new study. So it looked to me like one of the key questions here was this issue of time. If you increase the stress on a cell, iron overload and so forth, there's a difference between an acute stressor, which a cell might be able to deal with to some extent right now, versus a chronic stressor where, you know, over time you're wearing down antiaccident systems or something like this, so that even though the cell could deal with some of this oxidative stress for a while, at some point it can no longer keep up with it, and then, you know, you've got a problem.

Nick JikomesSo what was sort of the basic setup and motivation for the recent paper on chronofaroptosis?

Pamela MaherYeah, well, it was what I mentioned that we and others have been saying for a long time that the therapeutosis is involved in neurodegenerative diseases and other... well, particularly neurodegenerative diseases. And we've been gotten pushback because people say, well, like in particularly say in Alzheimer's disease, the nerve cells really don't die until much, much later in the disease. But then you're telling us it's involved in potentially development and certainly the progression of the disease.

Pamela MaherSo, you know, the people were saying, we don't buy this because you're in culture, cells die very quickly from when you activate this pathway. And so we would expect to see massive, if it's involved in AED, massive nerve cell death early on, and that's not what's seen. And that's the case. Well, with Parkinson's, there is more death, at least in the substantia nigra, probably, earlier on.

Pamela MaherBut nevertheless, this seemed to be a real contradiction that we needed to try and resolve. And so we from some, and we got some hints of this from some studies we've done with Salvador Soriano at Loma Linda University and his lab, one of the areas they've been interested in is a genetic peripheral neuropathy called Charcot-Marie-Tooth syndrome. And in this case, it's actually not neurocells that, so this is a progressive neuropathy. It's genetically inherited.

Pamela MaherThere's a number of different mutations that can lead to this disease, but the most common form is a mutation in a protein involved in myelin synthesis by Schwann cells. called PMP 22. And that's, so this occurs, it's an age-dependent disease. So people, most people don't get symptoms until they're in their 40s or 50s. And it, they, as I said, it's a peripheral neuropathy. So they develop problems with, you know, walking and then also in their hands and arms, but it has no impact on cognitive function. And so his lab was, they were, knew about our work on, well, what we called originally oxytocin, but baroptosis, but they thought that it, based on what was known from the literature in this disease, that perhaps this therapeutosis was involved, but not as a death pathway, more as a therapeutic stress pathway.

Pamela MaherBecause the Schwann cells, which are the impacted cells here, not nerve cells. So Schwann cells are the cells in the periphery that make myelin, that coats the neurons. the axons. And they so they developed they based on some both some cell culture studies as well as more looking at transcriptomic data that was actually already out there developed evidence that this pathway might indeed be activated in the context of sarcoma or E2 syndrome, but again, not as a death pathway, at least until much later, but again, more as a stress pathway where these changes that I told you about, increases in lipid peroxidation, decreases in glutathione, changes and other changes in iron lead to cellular dysfunction. And that's really what contributes to the disease and only later cell death. And so based on that, we were interested in, well, With that idea, with some suggestion already that this might actually happen in vivo, we decided to see if we could develop a model in the lab where we could compare a cell-based model, acute versus chronic stress, and specifically focus on stressors associated with this pharaohsiosis pathway.

Nick JikomesYeah, and so how are you actually stressing cells and putting them in this chronic stressed state?

Pamela MaherSo we used two approaches. One is to give them chronic excess iron, which is already known to be well changed in the context of mild cognitive impairment and more so in, in the AD, in the regions of the brain that are affected in Alzheimer's disease. And we also used glutathione, partial glutathione depletion, which also glutathione levels have been known for, particularly in the context of Parkinson's disease to be very much decreased in the region of the brain that's most affected, the substantia nigra. And early on before there's really significant loss of neurons in that region of the brain.

Pamela MaherSo both of these changes are seen in the context of increased iron and decreased glutathione in the context of neurodegenerative diseases. And with newer techniques they've shown, it used to be that you had to look at samples from autopsy brains, but now they have techniques to look at both glutathione as well as iron in the brains of living subjects. This has confirmed, the ability to look at this in living subjects has confirmed that these changes indeed do happen fairly early on in the disease and are likely to be contributing factors. So that was why we use these two insults and use them.

Pamela MaherNawab Dar, the postdoc in my lab that led this study, he used a cell line called SHSY-5Y cells, which can be differentiated into neurons. And then he treated these with either acute iron, the same concentrations or chronic iron levels, say for nine days to see if he could sort of mimic this idea or to see if he could see differences between how cells responded to an acute exposure versus long-term exposure, which, I mean, it's only nine days, it's not, you know, years, but it's still, you know, we felt somewhat mimicked the different, potentially the difference between... Yeah, might be more relevant to what was happening.

Nick JikomesYeah, so to kind of review so far, lipid peroxidation produces cell toxins that can ultimately kill the cell. One thing that can increase lipid peroxidation is excess iron. Another thing that can increase lipid peroxidation is depletion of glutathione antioxidant systems. So these are two different ways, they're not mutually exclusive, that a cell can become more sensitive to lipid peroxidation. and this therapeutic state. And we know that in neurodegenerative diseases in humans, in certain parts of the brain, depending on the disease, you either see iron overload, basically signs of excess iron and or depletion of antioxidant systems like glutathione.

Pamela MaherYeah.

Nick JikomesOkay, so walk us through the next step of the experiments you guys just did. So you did this nine day long experiment. So it's nine days long, as opposed to a few hours long, and the cells are in this more susceptible state. What did you observe after that?

Pamela MaherWell, we looked at a number of changes. We first focused on proteins, some of the key proteins in the therapeutosis pathway. we were surprised, really surprised, actually. And we always compared the acute treatment with the chronic treatment, again, using the same concentrations of either iron or an inhibitor of glutathione biosynthesis.

Pamela MaherInitially, when we did the studies, Nawab did the studies with iron, he was really surprised to find that while the acute treatment with iron had no effect on this enzyme that I told you about, glutathione peroxidase-4, is the key enzyme for removing lipid peroxides. Chronic treatment led to a reduction in GPX4 levels, a big reduction. It also led to changes in several iron handling proteins, as well as including ferritin. But the which was not unexpected, because when we actually looked at the levels of free iron in the cells, in the acute treatment, we saw a sharp increase in free iron over the course of the experiment.

Pamela MaherBut over the chronic treatment, we actually saw an increase a decrease in free iron, which correlated with the increase, a big increase in ferritin after a few days, in this case, a few days of treatment. But the decrease in GPX4, glutathione peroxidase 4, was very surprising because there was, there's still, this is something we're continuing to study, but why it seems why this chronic iron would change the expression of that protein, or the levels of that protein so dramatically is completely unclear, but suggests that chronic exposure to some of these insults, I guess you'd say, that are associated with the aging brain in the context of these neurodegenerative diseases, that they could make these changes, drive some changes in enzymes, or this enzyme in particular, that normally you would think that the cell would up-regulate as a protective mechanism was very surprising.

Nick JikomesSo basically, you do some iron overload of the cell for a little while, and there's more iron around, but the antioxidant systems that can deal with the lipid peroxides that might be forming are in place, and so it's not that big of a deal. But if you overload the cell with iron for several days, now you've got iron overload And for some reason or another, you deplete this glutathione peroxidase enzyme, and now the cell's actually got a weakened ability to deal with the lipid peroxidation byproducts that are gonna form and damage the cell.

Pamela MaherYeah, yeah, and so we looked at lipid peroxidation in the cells, and we found indeed that the acute treatment had no effect on the levels of lipid peroxidation, whereas the chronic treatment, we saw a dose-dependent increase in the levels of I guess you'd say chronic lipid peroxidation in the cells. And that correlated with some also alterations in the production of mitochondrial reactive oxygen species and changes in the mitochondrial membrane potential, which also correlated is can be a driver of reactive oxygen species production.

Nick JikomesSo basically you can stress a cell with iron overload. If you do that a little bit for a little while, the cell's basically fine, it's viable, its antioxidant systems aren't affected and it can deal with any lipid peroxidation that might happen. And you don't really see that much lipid peroxidation being induced. But if you just extend that iron overload for longer, now the antioxidant systems become depleted and the cell is now more susceptible to damage from lipid peroxidation.

Pamela MaherYes, yeah, yeah. And so what we found was that that was indeed the case, because then when we added either a low dose of a compound that directly induces the ferruptosis pathway, or a general oxidant, hydrogen peroxide, to the outside of cells, which we know actually does not induce ferruptosis, we found that there were even bigger increases in lipid peroxidation, and also the cells were now more likely, there was increased cell death. So I didn't mention, and this is important, that the levels of iron we used were not killing the cells, nor would the, the level of loss of glutathione, the cells weren't dying until we added an additional insult.

Pamela MaherAnd then we did see increased susceptibility to death. And what was the most interesting, it wasn't necessarily surprising that we, given that with, particularly with the iron, that it's already, known to help drive therapeutosis that when we added a therapeutosis inducer we did see some cell death but when we added hydrogen peroxide at a level which by itself wasn't didn't did kill cells under the acute condition, we did see increased cell death under the chronic condition.

Nick JikomesYeah. So some iron overload, but not enough to kill the cell, isn't killing the cell on its own, but it's putting it into this more susceptible state where now if you add another stressor that also wouldn't ordinarily kill the cell, now all of a sudden the cell's more susceptible and that stressor that was relatively benign before is now causing lipid peroxidation and even cell death.

Pamela MaherIt's increasing lipid peroxidation and yes, causing cell death. Yeah.

Nick JikomesYeah. Are there any particular lipid peroxidation products like HNE or MDA, any specific ones that seem to be doing the damage here or is it kind of a general- We actually, that's a good question, but we haven't explored that yet.

Pamela MaherWe didn't look at the specific lipid peroxides or products of lipid peroxidation. But yeah, I mean, we wanted to, get this paper out there and kind of establish the idea. And then going forward, we plan to explore various aspects, details of what's exactly what's going on. For instance, as I mentioned, what's happening and why are glutathione peroxidase four levels going down?

Pamela MaherAnd also, Are there specific, your question is a good one. Are there specific products of lipid peroxidation that are increasing and perhaps, you know, going further, are there specific, because as I mentioned, these, you know, the HNE and the maldenaldehyde can bind to proteins. So are there specific targets of this that might be particularly relevant to the changes that are occurring in the cells?

Nick JikomesDo we know anything about the polyunsaturated fats that are actually driving this lipid peroxidation? Are there specific polyunsaturated fatty acids that are predominantly driving it or is it all of them? And related to that, how much do the levels of polyunsaturated fats actually change in the cell? Can they go up and down by quite a bit or are they relatively stable?

Pamela MaherFrom other people's studies, the phospholipid that seems to be most susceptible to being altered in the context of pharoptosis is phosphatidylethanolamine. So that's the head group, and then it has fatty acids. But phospholipids contain, phosphoethanolamine phospholipids seem to be the most susceptible. I don't think anybody knows exactly why. They're fairly abundant in membranes, but I'm not sure they're, I don't think they're the most abundant of the phospholipids. The cells can change the levels of phospholipids fairly, fairly dynamically in various membranes. And as I said, some of the compounds we've identified that seem to be protective against this pathway, modulate fatty acid synthesis. And so, and they're protective pretty, quickly.

Nick JikomesSo, um, yeah, you mentioned that there's, there's compounds that modulate fat acid synthesis, so you can protect a cell or make it less susceptible to lipid peroxidation simply by decreasing the amount of polyunsaturated fats that are being produced and put into the membrane.

Pamela MaherWe, well, we think that's what's happening. Yeah. But, um, we, we actually, we, We don't know for sure if we're actually decreasing the levels of the polyunsaturated fatty acids in the membranes.

Nick JikomesAnd to what extent, if we kind of step back from this particular body of work for a second, and just talk about lipid peroxidation in general, to what extent is this a phenomenon that we see mostly in in vitro studies in a dish? And to what extent do we think this is actually happening in vivo in human beings? Are there markers or things that we can measure in humans that tell us that this is happening to some degree? Or is this likely to be something that happens in a very different way or to a very different extent in model systems like the ones you're using compared to in living, breathing animals?

Pamela MaherOh, no, there's actually quite a body of literature going back, oh, maybe 20 years, more evidence of lipid, or maybe more, yeah, 20 years, evidence of lipid peroxidation in samples from autopsy brains generally. of particularly AD patients and also some other Parkinson's disease patients and I believe some other neurodegenerative diseases. So this is something, so mostly people have relied on these modifications that I mentioned that occur subsequent to lipid peroxidation through either this molecule called hydroxynonanol or maldenaldehyde or a couple of other products of lipid peroxidation that react covalently with proteins. And so you can use them as, and their production is specific to lipid peroxidation.

Pamela MaherSo you can use them as markers of lipid peroxidation, which makes them quite suitable for looking at on autopsy tissues.

Nick Jikomeslipid peroxidation was in fact happening?

Pamela MaherNo. Well, they bind actually covalently to proteins. So they specifically bind to lysine residues in proteins. And so whether that is the cause of potentially impacting the function of these proteins and whether every protein that binds these is altered. I don't believe it's known, but because the binding is covalent, it's very stable. And so that makes them particularly... And there are antibodies. There are various ways you can detect them by mass spectrometry, but there are also antibodies to these groups that can be used, say, for looking at sections using immunofluorescence microscopy or by a technique called Western blotting where you separate proteins on a gel by size and can then probe the different proteins with these antibodies.

Nick JikomesYeah, so lipid peroxidation, you know, it does happen in our own cells and tissues to some degree or another, it's probably gonna happen to different degrees, depending on your relative state of, you know, health, metabolic health, whether you're diseased, your total antioxidant, stress capacity, and so on and so forth. So it's not just something that happens in, you know, in a dish under contrived circumstances.

Pamela MaherOh, well, I should say to that. There's been numerous studies in animal models, looking at theraptosis in the context of a variety of different diseases, not just neurodegenerative disease, but also various liver toxicities, cardiac, different forms of ischemia, cardiac ischemia, or cardiac toxins, kidney toxins. from groups all over the place. And almost everybody, if they're looking at ferritosis, has looked at lipid peroxidation.

Pamela MaherIf they can get fresh tissue, then they can use some of these other probes for lipid peroxidation. But usually, often they use these other markers. But yeah, in terms of it happening in vivo, in the context of various diseases, there's, yeah, really, an overwhelming amount of data that suggests that indeed this occurs in a variety of different contexts.

Nick JikomesAnd when we look at the literature there and we look at the animal studies that have been done, are there any things that can, any manipulations that can be done, changes in the diet, giving exogenous compounds, perhaps some of the ones you mentioned before, they can actually prevent or reduce the amount of lipid peroxidation that's happening in various tissues?

Pamela MaherYeah, well, as I think I mentioned earlier, some of these two kind of ferrostatin or liproxstatin, which are the direct inhibitors of lipid peroxidation, in experimental models, people have often seen effects with those, because they're trying to show that this ferroptosis pathway is involved in whatever they're... disease that they're interested in. So they've had focused on these well, inhibitors that everybody agrees blocks this pathway. So, but there's other, I mean, people have used other compounds to show that target, particularly say if they think a specific pathway might be involved, they've used compounds that modulate those specific pathways.

Pamela MaherAs I mentioned earlier, you gotta be a little careful with those in case the compound they're using actually also inhibits lipid peroxidation.

Nick JikomesAnd can you give us a sense for like, where do you guys wanna go Next, with respect to this stuff, this chronophereoptotic state where the cells are more susceptible and how it ties into neurodegenerative disease, where do you see this going in terms of mapping out how all this works and developing ways to treat things like neurodegeneration by preventing or inhibiting in some way lipid peroxidation from happening?

Pamela MaherWell, in terms of where it goes next, as I said, we want to use our culture model to understand why is, say, chronic iron or chronic glutathione depletion, or how mechanistically it's driving some of the changes that we saw. But we also want to establish this more clearly in tissues and in animal models. So initially, we're thinking of using like tissue slices to characterize it more fully in tissues like the brain or the brain tissue. as a peripheral tissue, say the liver, where we can see if different types of cells perhaps in these tissues are more susceptible to changes, say initially changes in lipid peroxidation, which there are good fluorescent dyes to be able to monitor that.

Pamela Maherunderstand what types of cells, you know, are all cells susceptible, say in the brain, are the nerve cells particularly susceptible to this? And, or are other types of cells also susceptible? And Also, our idea is that the susceptibility may change in the context of aging. So, as I said, initially, we're hoping to use just isolated tissues where we make slices from different aged mice, say, and look at the susceptibility to activation of this pathway in different cell types.

Pamela MaherBut we'd also, like to pursue this in in vivo models. I mean, there are definitely models of iron overload in animals. Advantage of using the tissue slices initially is that all of the cells are exposed to the same level of, would be say of iron or even an inducer, low levels of an inducer, a direct inducer of ferreptosis. Whereas when you administer it systemically, different cell types may be exposed differently.

Pamela MaherAnd so that makes it a little harder to interpret that cell type sensitivity. But the goal, eventually, is to test some of these ideas in animal models and see if, indeed, we can, there's a fair amount of literature on iron overload, and it does suggest that it can contribute to cognitive dysfunction, particularly in the context of aging. So, yeah. it would be more tying this more directly to this therapeutic stressor.

Nick JikomesAnd I think you mentioned earlier that when we look at tissues from autopsies from individuals who had Alzheimer's and other neurodegenerative diseases, we see indications of iron overload in the parts of the brain that are degenerating. Obviously you guys can induce iron overload in your experimental systems, Um, do we know much about what causes iron overload to you know, people out in the world? Are there dietary factors here? Do certain diseases cause it just as part of the disease? Where does iron overload actually where do we actually see it in people?

Pamela MaherUm The well there is one disease, uh chemo chromo

Nick Jikomeshemochromatosis.

Pamela MaherYes. Okay. And that although that's interesting, because Males with that disease, at least with certain mutations, not all, there's a number of different mutations that can cause that disease, which is an iron overload, a systemic iron overload disease. Males with that disease do, and I said, specific mutations do tend to develop cognitive problems, but females don't, so they don't understand that.

Pamela MaherSo that's an interesting area, perhaps, of looking at these Brazilian spiders that I was talking, potentially earlier. The other reason cells might develop iron overload, particularly in the context of aging, is changes in proteins that handle iron, either bring iron into cells or move it out. So a protein, I think you mentioned earlier, the transferrin receptor is the main protein for bringing iron into cells, that's quite dynamically regulated. But if that And then there's a protein, actually the only protein that's involved in export of iron, that's called ferroportin.

Pamela MaherAnd that could also, I think there's some evidence that that changes in the context of at least of Alzheimer's disease. I don't know if it's explored, though it goes down, but exactly in which cells. And there also may be changes, and I don't think this has been explored all that much, in how iron is passed in the context of the brain, particularly between cells in the brain, and whether some of those systems may also change in the context of aging. So I think there's iron metabolism.

Pamela MaherMetabolism is fairly complex. And so I think there's further avenues for exploration in the context of, particularly just in the context of aging. I should say, however, that Iron chelators, at least the ones they have tried so far, have not worked in patients in either Parkinson's or in Alzheimer's disease patients. And so it's not entirely clear why they have failed because people, given all this evidence for the increase in iron, that and the evidence that how iron can be detrimental.

Pamela MaherSo in both cases, it was very disappointing, both for the investigators and the patients, but just for the general community that's interested in these diseases, that the iron chelators really failed quite well. dramatically in terms of providing any benefits. And it may be that the problem are they just chelate too much iron. As I mentioned, iron is important for these mitochondrial proteins and other, the function of other proteins in cells.

Pamela MaherSo it may be that most of these iron chelators are pretty non, are nonspecific and maybe they just took out both the bad iron, the iron that potentially could cause damage, but also the iron that's needed for key cellular functions.

Nick JikomesRight, right. Yeah, as with most things in biology, you don't want too much or too little.

Pamela MaherYeah, yeah. No, that's, so I think I would, I would guess that some of the labs that are really interested, we're working iron design, on iron chelation as a potential therapeutic, maybe they're still exploring whether there are better iron chelators out there that might not be quite as specific. I mean, well, might be more specific to get rid of, say, labile iron, but might not chelate other forms of iron that might be needed for cellular functions, or whether they decided that moving into other approaches might be more appropriate.

Nick JikomesYeah. Are there any final thoughts you want to leave people with or anything you want to reiterate from our conversation today as it relates to oxidative stress, cell health, and lipid peroxidation, especially in the context of neurodegenerative disease?

Pamela MaherWell, I think There's been one of the things that's come out of numerous studies where people have looked at lifestyle factors, particularly in the context of dementia, Alzheimer's or other types of dementia. One of the... points that often it comes out of these are diet and how a diet that's rich in fruits and vegetables and other nuts and other products and lower in fats and can be beneficial in terms of reducing the risk of developing dementia. So that would fit with the ideas of kind of overall that having more antioxidants or more compounds that can activate.

Pamela MaherI didn't mention there's a protective pathway called, that's mediated by a transcription factor called NRF2, which regulates the synthesis of a variety of antioxidant enzymes, including this enzyme GPX, glutathione peroxidase-4. And there's, quite a bit of data that activation of that pathway can be protective against the periptosis and periptonic stress. And a number of dietary compounds are able to activate that pathway as well. Well, what are those?

Pamela MaherWell, there's a compound in broccoli called sulforaphane that can activate the pathway of that compound I mentioned, the flavonoid, Fisetin, and the other one I mentioned, Stirubin, can activate the pathway. Those are in, well, Fisetin is in a variety of, particularly in strawberries, but probably not at concentrations that would be sufficient to activate the pathway. I think people, there's another one, Quercetin, which is found in, a variety of, particularly it's the yellow color and yellow onions, but it's also found in other fruits and vegetables. And so I think just having a variety of fruits and vegetables that maybe these compounds individually aren't sufficient, but in combination would be enough if you're consuming these on a daily basis too.

Nick JikomesSo there are dietary components, such as some of the examples you just shared, and these things can affect the transcription factor that's responsible for upregulating the antioxidant enzyme that we talked about before.

Pamela MaherYeah, and others as well that seem to provide other checks and balances on this pathway. Yes. So I think that would be right now, you know, there's a lot of other risk factors for dementia, but in relation to what specifically ties into this chronophereptosis and also that people can do something about. I think, yeah, modulating diet has a strong potential to be helpful.

Nick JikomesAll right. Well, Dr. Pam Lamar, thank you again for joining me. I really enjoyed this. And yeah, again, thank you for your time.

Pamela MaherOkay. Well, thanks for having me.

Nick JikomesHey everyone, a great way to support my efforts is to visit my support page at mindandmatter.substack.com. A link to that page is in the episode description or you can search for it on the Substack page itself. The support page has an up-to-date list of my affiliate partners. These are companies I work with and if you buy those products through those links or using the discount codes provided, Those will get you a great deal on a variety of products related to optimizing physical, metabolic, or mental health and vitality.

Nick JikomesThese are all products I use myself, and some of them are directly related to podcast episodes or formulated by Minded Matter guests. For example, there's a great product called Keto Citra formulated by a kidney biologist who is on episode number 186. It contains the ketone body BHB together with several minerals in a precise ratio formulated with kidney health in mind. also links to products like physical technology devices to track your metabolic health, digital applications to help you find and learn about food and consumer products, and more. One product I use every day is the AquaTrue water filter. I recommend this to everyone because it gets everything out of your drinking water, heavy metals, microbes, endocrine disruptors, microplastics, you name it. Other charcoal or gravity-based filters that a lot of people use don't get everything out, they just get some of the stuff out. So I really like the AquaTrue product.

Nick JikomesYou can look for a link to my affiliate partners on my support page or directly in the episode description to this episode, or you can go to mindandmatter.substack.com to find it there.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Seed Oils, Omega-3s & Lessons From 93 Years of Life | Artemis Simopoulos | 313

    Nov 17, 20261 hr 35 minAudio

    Send us Fan Mail At 93, Artemis Simopoulos explains why oils once used in paint now dominate the food supply, how a high omega-6 intake slows the making of EPA and DHA, and why cholesterol-lowering corn oil did not...

    Credit the people on this episode

  2. Tendons, Collagen, mTOR & Exercise Adaptation | Keith Baar | Episode 312

    Nov 10, 20262 hrAudio

    Send us Fan Mail Keith Baar explains why tendons stop adapting after 10 minutes of loading, why long low-load holds beat fast reps for connective tissue, and how vitamin C, collagen, caffeine and mTOR shape training....

    Credit the people on this episode

  3. GDF15, Morning Sickness & Mitochondrial Stress | Stephen O'Rahilly | Episode 311

    Nov 3, 20261 hr 29 minAudio

    Send us Fan Mail Dr. Stephen O'Rahilly explains GDF15, a stress hormone that makes us feel sick and eat less, and why morning sickness, and its severe form hyperemesis gravidarum (HG), comes from GDF15 made by the...

    Credit the people on this episode

  4. Psilocybin vs. SSRIs for Depression, Emotional Blunting & How Psychedelics Work | Robin Carhart-Harris | 310

    Oct 26, 20261 hr 56 minAudio

    Send us Fan Mail Robin Carhart-Harris explains why his trial of psilocybin therapy vs. the SSRI escitalopram for depression missed one primary measure but favored psilocybin on almost everything else, and why SSRIs can...

    Credit the people on this episode

  5. This Animal Survives 18 Minutes Without Oxygen | Gary Lewin | 309

    Oct 12, 20261 hr 40 minAudio

    Send us Fan Mail Nick talks with Prof. Gary Lewin (Max Delbrück Center, Berlin) about naked mole-rats, which in lab tests survived 18 minutes in pure nitrogen by shutting down brain activity, keeping the heart beating,...

    Credit the people on this episode